Grantham Mayo Van Otterloo & Co. LLC Takes $22.78 Million Position in Moderna, Inc. (NASDAQ:MRNA)

Grantham Mayo Van Otterloo & Co. LLC acquired a new position in Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 547,812 shares of the company’s stock, valued at approximately $22,778,000.

Several other institutional investors have also added to or reduced their stakes in MRNA. Wilmington Savings Fund Society FSB lifted its position in shares of Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the period. Compass Planning Associates Inc bought a new position in Moderna during the fourth quarter worth $37,000. Venturi Wealth Management LLC raised its stake in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares during the last quarter. Crowley Wealth Management Inc. acquired a new position in Moderna in the fourth quarter valued at $41,000. Finally, MassMutual Private Wealth & Trust FSB boosted its position in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after acquiring an additional 389 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Performance

NASDAQ MRNA opened at $25.11 on Friday. The company has a market capitalization of $9.71 billion, a PE ratio of -2.71 and a beta of 2.23. Moderna, Inc. has a 52-week low of $23.76 and a 52-week high of $170.47. The company has a 50-day simple moving average of $33.55 and a 200 day simple moving average of $42.80.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on MRNA shares. Citigroup began coverage on Moderna in a research note on Thursday, March 13th. They set a “neutral” rating and a $40.00 target price for the company. Morgan Stanley dropped their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. Bank of America reduced their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Finally, Leerink Partners cut their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and an average target price of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.